Patents by Inventor Yosef Refaeli

Yosef Refaeli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conditionally immortalized long-term stem cells and methods of making and using such cells
    Patent number: 9796961
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: October 24, 2017
    Assignees: The Regents of the University of Colorado, National Jewish Health
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
    Patent number: 9789135
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: October 17, 2017
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
  • Modulators of MYC and methods of using the same
    Patent number: 9775897
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: October 3, 2017
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • ANTIBODIES AND PROCESSES FOR PREPARING THE SAME
    Publication number: 20170044237
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Application
    Filed: August 23, 2016
    Publication date: February 16, 2017
    Inventors: Yosef REFAELI, Brian Turner
  • THERAPEUTIC APPLICATIONS OF SMAD7
    Publication number: 20170014479
    Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Inventors: Xiao-jing WANG, Yosef REFAELI, Qinghong ZHANG
  • PTD-SMAD7 THERAPEUTICS
    Publication number: 20170000851
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 5, 2017
    Inventors: Xiao-Jing WANG, Qinghong ZHANG, Yosef REFAELI
  • EXPANSION OF ADULT STEM CELLS IN VITRO
    Publication number: 20160355785
    Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
    Type: Application
    Filed: June 10, 2016
    Publication date: December 8, 2016
    Inventors: Brian Curtis TURNER, Yosef REFAELI, Gregory BIRD
  • Therapeutic applications of SMAD7
    Patent number: 9474784
    Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: October 25, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Xiao-jing Wang, Yosef Refaeli, Qinghong Zhang
  • Antibodies and processes for preparing the same
    Patent number: 9428571
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: August 30, 2016
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Turner
  • PTD-SMAD7 therapeutics
    Patent number: 9422352
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: August 23, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Xiao-Jing Wang, Qinghong Zhang, Yosef Refaeli
  • Expansion of adult stem cells in vitro
    Patent number: 9365825
    Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 14, 2016
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Bird
  • CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
    Publication number: 20160040129
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: October 2, 2015
    Publication date: February 11, 2016
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis Turner
  • PTD-SMAD7 THERAPEUTICS
    Publication number: 20160039894
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Application
    Filed: March 7, 2014
    Publication date: February 11, 2016
    Inventors: Xiao-Jing WANG, Qinghong ZHANG, Yosef REFAELI
  • Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
    Patent number: 9169462
    Abstract: Provided herein are methods for preparing differentiated cells, and the cells prepared by such methods.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: October 27, 2015
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • THERAPEUTIC APPLICATIONS OF SMAD7
    Publication number: 20150290287
    Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.
    Type: Application
    Filed: June 25, 2015
    Publication date: October 15, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Xiao-jing WANG, Yosef REFAELI, Qinghong ZHANG
  • Conditionally immortalized long-term stem cells and methods of making and using such cells
    Patent number: 9150831
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: October 6, 2015
    Assignees: The Regents of the University of Colorado, National Jewish Health
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • ANTIBODIES AND PROCESSES FOR PREPARING THE SAME
    Publication number: 20150259399
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Application
    Filed: March 18, 2015
    Publication date: September 17, 2015
    Inventors: Yosef REFAELI, Brian TURNER
  • CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
    Publication number: 20150240205
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Application
    Filed: October 8, 2014
    Publication date: August 27, 2015
    Inventors: John C. CAMBIER, Yosef REFAELI, Sara Ann JOHNSON, Brian Curtis Turner
  • ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT
    Publication number: 20150164950
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Application
    Filed: July 19, 2013
    Publication date: June 18, 2015
    Applicant: Taiga Biotechnologies, Inc.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird
  • Antibodies and processes for preparing the same
    Patent number: 8986702
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: March 24, 2015
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner